BTK inhibitor
Bruton tyrosine kinase inhibitor
- Interrupts B-cell receptor signaling
- Impairs B-cell survival/proliferation → treats B-cell malignancies
- ↓ mast-cell/basophil FcεRI signaling → ↓ urticaria
- Bleeding
- Atrial fibrillation
- Blocks B-cell receptor signaling in CLL and lymphoma
- Bleeding and atrial fibrillation risk
Drugs with this mechanism (5)
- Acalabrutinib — Second-generation covalent BTK inhibitor with less atrial fibrillation than ibrutinib.
- Ibrutinib — BTK inhibitor for B-cell cancers; bleeding and atrial fibrillation.
- Pirtobrutinib — Noncovalent BTK inhibitor that remains active after many covalent BTK inhibitors fail.
- Remibrutinib — Oral BTK inhibitor for antihistamine-refractory chronic spontaneous urticaria.
- Zanubrutinib — More selective covalent BTK inhibitor for CLL, mantle cell lymphoma, and Waldenstrom macroglobulinemia.
All mechanisms · Open BTK inhibitor in the interactive console ↗